Published: 2019-02-26 11:15 | Updated: 2019-10-29 18:05

3TR – a precision medicine endeavour

Professor Sven-Erik Dahlén, IMM, participates in the co-ordination team of the IMI project 3TR that was recently approved for funding by the European Commission.

Sven-Erik Dahlén, credit: Stefan Zimmerman.

3TR (Taxonomy, Treatment, Targets and Remission) will focus on the identification of the molecular mechanisms of non-response to treatments, relapses and remission in autoimmune, inflammatory, and allergic conditions. 3TR is a highly integrated and transdisciplinary consortium that proposes multi-dimensional molecular analysis of different biomarkers collected longitudinally from patient cohorts suffering from seven different inflammatory diseases (RA, SLE, MS, IBD, Mb Crohn, COPD and asthma).

The project will be coordinated by Professor Marta Alarcón-Riquelme, Fundación Pública Andaluza Progreso y Salud, Spain. She is also a visiting researcher at the Institute of Environmental Medicine (IMM), KI. 3TR has 70 partners (including universities, pharmaceutical companies, hospitals, SME’s, societies and patient organisations). The total budget will be 80 million EUR, of which 40 million EUR is contributed by the pharmaceutical industry. The project is estimated to start August 2019 and will run for 7 years.

The contributions to the project in Stockholm by Karolinska Institutet, Karolinska University Hospital and SciLifeLab will be coordinated by Sven-Erik Dahlén, Professor of Experimental Asthma and Allergy Research at IMM. From Sweden, the University of Örebro is also a partner in the project. 

The Innovative Medicines Initiative (IMI) is a partnership between the European Union and the European pharmaceutical industry, aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need.